EO9 PHASE-II STUDY IN ADVANCED BREAST, GASTRIC, PANCREATIC AND COLORECTAL-CARCINOMA BY THE EORTC EARLY CLINICAL-STUDIES GROUP

In a phase II trial, the activity of EO9, a new bioreductive alkylatin g agent, was assessed. EO9 was used as second-line chemotherapy in bre ast cancer patients and as first-line chemotherapy for patients with g astric, pancreatic and colorectal cancer. EO9 was given as a 5 min i.v . infusion at a weekly dose of 12 mg/m(2). 92 patients were entered; 2 2 with breast cancer, 26 with colon cancer, 24 with pancreatic cancer and 20 with gastric cancer. In general, the drug was well tolerated wi th nausea and vomiting occurring in 26.42 and 13.3% of courses, respec tively. Reversible proteinuria was the main toxicity occurring in 45% of courses. Antitumour activity was not observed. At this dose and sch edule, EO9 is not an active drug in the type of tumour studied. Copyri ght (C) 1996 Elsevier Science Ltd